BIOSIMILAR INFLIXIMAB (CT-P13) IS NOT INFERIOR TO ORIGINATOR INFLIXIMAB: RESULTS FROM THE 52-WEEK RANDOMIZED NOR-SWITCH TRIAL

Kristin K Jørgensen  1     Inge C Olsen  2     Guro L Goll  2     Merete Lorentzen  3     Nils Bolstad  4     Espen A Haavardsholm     Knut E.A. Lundin     Cato Mørk     Jørgen Jahnsen     Tore K Kvien    
1 Akershus University Hospital, Section of Gastroenterology, Lørenskog, Norway
2 Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway
3 Oslo University Hospital, Rikshospitalet, Department of Dermatology, Oslo, Norway
4 Department of Medical Biochemistry, Oslo Uni

Conference
UEG Week 2016

Citation
United European Gastroenterology Journal; 2016: 2 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing